Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · IEX Real-Time Price · USD
5.32
+0.10 (1.92%)
At close: Apr 26, 2024, 4:00 PM
5.39
+0.07 (1.32%)
After-hours: Apr 26, 2024, 7:57 PM EDT
Editas Medicine Revenue
In the year 2023, Editas Medicine had annual revenue of $78.12M with 296.32% growth. Revenue in the quarter ending December 31, 2023 was $60.05M with 818.74% year-over-year growth.
Revenue (ttm)
$78.12M
Revenue Growth
+296.32%
P/S Ratio
5.60
Revenue / Employee
$294,804
Employees
265
Market Cap
437.49M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
Dec 31, 2015 | 1.63M | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aveanna Healthcare Holdings | 1.90B |
ZimVie | 457.43M |
Sonida Senior Living | 255.32M |
Fate Therapeutics | 63.53M |
Theravance Biopharma | 57.42M |
C4 Therapeutics | 20.76M |
Taysha Gene Therapies | 15.45M |
Fulcrum Therapeutics | 2.81M |
EDIT News
- 4 days ago - Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 2 months ago - Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates - GlobeNewsWire
- 2 months ago - Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events - GlobeNewsWire
- 3 months ago - Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 - GlobeNewsWire
- 4 months ago - Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar - GlobeNewsWire